Global Evaluation of Cholecystectomy Knowledge and Outcomes

Gallbladder Cancer Clinical Trial

— GECKO  

Official title:

Global Evaluation of Cholecystectomy Knowledge and Outcomes

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06223061
• Other study ID #: GlobalSurg 4 Edinburgh
• Status: Active, not recruiting
• Start date: July 31, 2023
• Est. completion date: November 1, 2024

Study information

• Verified date: January 2024
• Source: University of Edinburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Cholecystectomy is amongst the most common surgical operations performed worldwide. Surgical candidates are treated for biliary pathologies, such as biliary colic, cholecystitis and gallstone pancreatitis. In patients who are deemed fit for surgery, cholecystectomy can be performed under three main settings: (1) emergency setting at index admission; (2) elective setting with no previous admissions; or (3) delayed setting with one or more previous gallbladder-related admissions.

The advent of laparoscopy fundamentally evolved biliary surgery and quickly became the "gold standard" approach. Recent multicentre collaborative studies have elucidated that the burden imposed on healthcare systems by laparoscopic cholecystectomies is primarily due to patient readmissions and complications arising from the operation, rather than perioperative mortality burden that was more commonly seen in open surgery. As a result, national and international societies have shifted their focus towards creating a culture of safety around this procedure, with the overarching goal of improving patient satisfaction and reducing hospital costs. The universal establishment of safe cholecystectomy is a complex process that relies not only on the operation itself, but also on various other factors such as promoting adequate training, improving hospital infrastructure, and enhancing perioperative patient care.

There remains a paucity of evidence around the variations of safe provision of laparoscopic surgery for gallbladder disease internationally, including low- and middle-income countries. To bridge this knowledge gap, the Global Evaluation of Cholecystectomy Knowledge and Outcomes (GECKO) study (GlobalSurg 4) will be an international collaborative effort, delivered by the GlobalSurg network, that will allow contemporaneous data collection on the quality of cholecystectomies using measures covering infrastructure, care processes and outcomes. It will be disseminated via contacts from the National Institute for Health and Care Research (NIHR) Global Surgery unit, leading emergency general surgeons and specialist organisations.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30000
• Est. completion date: November 1, 2024
• Est. primary completion date: November 19, 2023
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Age: All adult patients (greater than or including 18 years of age).

• Procedure: Primary cholecystectomy, where this is the main procedure planned.

• Approach: Open, laparoscopic (standard and single-port), and robotic. Gasless laparoscopic and robotic approaches are inluded. Laparoscopic and robot converted cases are also eligible.

• Urgency: Elective, delayed and emergency procedures.

Exclusion Criteria:

• Procedure: Patients having a cholecystectomy as a part of another surgical procedure; for example, Whipple's procedure, bariatric, anti-reflux, or transplant operations, should be excluded.

• Indication: Patients with Mirizzi syndrome should be excluded.

• Return to theatre: Each patient should only be entered into the study once. Any patient returning to theatre and requiring a cholecystectomy for whatever indication, should not be included.

• Known gallbladder malignancy: when the diagnosis of gallbladder cancer is established pre-operatively, the patient should be excluded. However, if gallbladder cancer is found unexpectedly during or after cholecystectomy (i.e. on histology), the patient should be included.

Related Conditions & MeSH terms

• Bile Duct Injury
• Gallbladder Cancer
• Gallbladder Neoplasms
• Gallstone
• Gallstones

Locations

Country	Name	City	State
United Kingdom	University of Edinburgh	Edinburgh

Sponsors (2)

Lead Sponsor	Collaborator
University of Edinburgh	University of Birmingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Compliance to pre-, intra-, and post-operative audit standards	Compliance to audit standards are defined as follows: Pre-operative: For patients with acute cholecystitis, surgeons may use the Tokyo Guidelines 18.; Intraoperative: The use of the critical view of safety during laparoscopic cholecystectomy is the recommended approach to correctly identify relevant anatomy and minimize the risk of bile duct injuries; Postoperative: 30-day readmission should be <10%.	30-days from surgery
Secondary	Quality of provision of cholecystectomy	The quality will be assessed according to the rates of overall complications defined as the presence of Grade I to grade V Clavien-Dindo complication.	30-days of surgery
Secondary	Adverse events following cholecystectomy (e.g., bile duct injury) and their management.	Occurence of bile duct injury within 30-days of surgery will be defined according to the Strasberg Classification	30-days of surgery
Secondary	Rates of unsuspected gallbladder cancer.	The rates of gallbladder cancer will be assessed at 1-year from the index surgery once the histology results are available.	1-year from surgery